New space for Outerspace Melbourne

8 March 2019 | Outerspace Melbourne has settled in the new makerspace in Abbotsford, a short drive from the old studio. The team enjoyed designing the “clean slate” space and making it their own, with an open layout…

Read More

Immutep presents positive IMP761 preclinical results

8 March 2019 | Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European…

Read More

Immutep doses first patient in TACTI-002 Phase II trial

8 March 2019 | Immutep has just announced that the first patient has been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of their lead product candidate, eftilagimod alpha (“efti”), and KEYTRUDA®…

Read More

Immutep announces data from ongoing TACTI-mel Phase I clinical trial in unresectable or metastatic melanoma

8 March 2019 | This week at the World Immunotherapy Congress 2019 in San Diego USA, Immutep announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the company’s lead product candidate, eftilagimod alpha…

Read More

Home

News & opinion

Member Directory

Events